RULING ON CLASS CERTIFICATION
Pеnding is a motion for class certification pursuant to Fed.R.Civ.P. 23 filed by the lead plaintiffs, David Berlin and Yinh Voung (collectively “plaintiffs”). The motion seeks certification of a class consisting of all persons who purchased PE Corporation Celera Genomics Group (“Celera”) common stock issued in a secondary public offering conducted by PE Corporation (“PE”) on February 29, 2000, and who were damaged thereby. For the following reasons, the motion is GRANTED.
I. Background
A) Genomic Science
PE is a Delaware corporation which conducts its business through its subsidiaries, Celera and PE Biosystems. Celera generates, sells and suppоrts genomic information and related information management and analysis software.
B) Human Genome
Celera reportedly began sequencing the human genome in September 1999, after it completed sequencing the genome of Drosophila (the fruit fly). Celera publicly announced in January 2000 that it had compiled ninety percent of the human genome. Other companies, both private and public, have been working to sequence the human genome as well. The most significant undertaking is being made by the Human Genome Project (“the Project”), a worldwide coordinated effort sponsored by governments and nonprofit organizations in the United States, England, Japan and France, among others. In the United States, the majority of the public funding for the Project is provided through the National Institutes of Health (“the NIH”).
Following Celera’s public announcement in January 2000 that it had mapped ninety percent of the human genome, NIH announced that it had reallocated funding in order to further accelerate the Project’s sequencing effort and to attempt to achieve a “working draft” of the genome by Spring 2000. Thus, Celera was in a “race” with the Project to complete the map of the human genome. The outcome was significant to Celera because the Project intended to make its findings publicly available, while Celera intended to license its findings to customers on a commercial basis. Specifically, Celera has publicly stated that its business strategy is to sequence the human genome and then “use the genomic information derived from its genomic sequencing program as a platform upon which to develop an integrated informa
C) Celera Common Stock
A secondary public offering of Celera common stock occurred on February 29, 2000. The price of Celera common stock rose sharply in the months preceding the secondary public offering. On September 14, 1999, Celera common stock traded for $17.88 per share. By February 28, 2000, following Celera’s public announcement in January that it had mapped ninety percent of the human genome, its stock traded for $239.00 per share-an increase of 1300%. On February 29, 2000, PE filed with the SEC a final Form S-3 Registration Statement (“the registration statement”) for the secondary public offering. On that same day, the prospectus for that offering became effective, and PE sold, through its underwriters, 3.8 million shares of Celera common stock at a price of $225.00 per share. In addition, PE purchased 570,-000 shares of Celera common stock from the underwriters through аn over-allotment option. The gross proceeds from the secondary offering, including the exercise of the over-allotment option, were approximately $944 million.
D) Loss of Value
The complaint further alleges that during the period preceding the secondary offering, when Celera and the Project appeared to be in competition to finish mapping the human genome, Celera and the Project were engaged in discussions to combine their efforts in order to finish the human genome project more quickly. Those discussions ultimately broke off because the pаrties were unable to come to an agreement concerning Celera’s demands that it have exclusive rights to the human genome map for an extended period of time. The discussion between Celera and the Project were not widely known by the public and were never referenced in Celera’s public filings or press releases, nor were they disclosed in the prospectus for the secondary offering of Celera’s common stock. More specifically, the complaint alleges that a story appearing in the Los Angeles Times on March 6, 2000, first revealed that Celera and the Project had been in ongoing discussion concerning their proposed collaboration, and had met on December 29, 1999, at Dulles International Airport near Washington, D.C. Following the publication of the story in the Times, the price of Celera common stock declined from $247.00 per share, on March 6, 2000, to $189.00 per share on March 13, 2000.
The complaint also alleges that on March 14, 2000, President Clinton and Prime Minister Blair of the United Kingdom issued a major, joint statement in which they reiterated the position of their respective governments that all information about gene sequencing аnd the human genome project should be publicly available. This announcement made it clear that the power of the U.S. and U.K. governments would be brought to bear to oppose any efforts to obtain exclusive rights to the sequencing of the human genome for any protracted period of time and to obtain patent and copyright protection of information obtained from the sequencing. After this announcement, the price of Celera common stock further declined from $189 per share to approximately $119-almost fifty percent less than it was sold for in the secondary offering fourteen days earlier. This decline continued over the next several months, and, on August 17, 2001, Celera common stock closed at $26.21.
II. Procedural History
In 2000, four cases were filed in the United States District Court for the District of Connecticut alleging that the defendants had violated federal securities laws in connection with the sale of Celera common stock through the secondary offering. On August 4, 2000, those four cases were consolidated into one action before this Court, under the heading “In Re: PE Corporation Securities Litigation.” On July 6, 2001, this Court ap
III. Law
The plaintiffs seek class certification pursuant to Fed.R.Civ.P. 23. Under Rule 23, there is a two-part inquiry for class certification. First, a court must determine whether the plaintiffs satisfy the four requiremеnts of Rule 23(a), which provides:
One or more members of a class may sue or be sued as representative parties on behalf of all only if (1) the class is so numerous that joinder of all members is impracticable, (2) there are questions of law or fact common to the class, (3) the claims or defenses of the representative parties are typical of the claims or defenses of the class, and (4) the representative parties will fairly and adequately protect the interests of the class.
Fed.R.Civ.P. 23(a); see also General Tel. Co. of the Southwest v. Falcon,
Second, the Court must determine whether the plaintiffs have satisfied one of the prongs of Rule 23(b). Here, the plaintiffs argue that a class is maintainable under section (b)(3) of Rule 23, which provides, in relevant part:
(b) Class Actions Maintainable. An action may be maintained as a class action if the prerequisites of subdivision (a) are satisfied, and in addition: ... (3) the court finds that' the questions of law or fact common to the members of the class predominate over any questions affecting only individual members, and that a class action is superior to other available methods for the fair and efficient adjudication of the controversy____
Fed.R.Civ.P. 23(b)(3).
“In light of the importance of the class action device in securities fraud suits, these factors are to be construed liberally.” Gary Plastic Packaging Corp. v. Merrill,
IV. Analysis
As noted previously, the Court must first address the four criteria of Rule 23(a): numerosity, commonality, typicality, and adequacy of representation. Fed.R.Civ.P. 23(a); see also In re PolyMedica Corp. Securities Litigation,
1) Numerosity
The defendants have not contested the ability of the purported class to meet the numerosity requirement. Under Rule 23(a)(1), plaintiffs need not prove the exact number of proposed class members as long as they can reasonably estimate the size of the class. See Garfinkel v. Memory Metals, Inc.,
2) Commonality
The defendants have also not challenged the plaintiffs’ showing of commonality under Rule 23(a)(2), apparently conceding that there is a uniform course of conduct applied to all purported class members. Rule 23(a)(2) requires the existence of “questions of law or fact common to the class.” See also Marisol A,
In this case, all of the claims concern the allegedly false and misleading statements made in the prospectus for the secondary offering of Celera common stock. Consequently, at this stage of the analysis, the Court finds that the purported class meets the commonality requirement. See Korn v. Franchard Corp.,
3) Typicality
Rule 23(a)(3) requires that “the claims or defenses of the rеpresentative parties are typical of the claims or defenses of the class.” “Typicality ... requires that the claims of the class representatives be typical of those of the class, and is satisfied when each class member’s claim arises from the same course of events, and each class member makes similar legal arguments to prove the defendant’s liability.” Marisol A.,
The complaint sets forth claims under Sections 11, 12 and 15 of the 1933 Act. The defendants contend that the claims of the proposed сlass representatives, Berlin and Voung, are not typical because neither party can set forth successful claims under Section 11 or 12 due to the manner in which they purchased Celera common stock. This argument is unpersuasive. Here, the putative class, including the plaintiffs, put forth one claim, namely whether the prospectus issued for the secondary offering of Celera stock contained false or misleading information. There was only one prospectus issued, and it applied equally to all purchases of stock during that secondary offering. Although the defendants may be able to prove that Berlin and Voung purchased some of their shares
Therefore, the plaintiffs have proven that “the claims of the representative parties are typical of the claims or defenses of the class” and thus, have adequately satisfied the typicality requirement of Rule 23(a)(3). See Steinberg v. Nationwide Mut. Ins. Co.,
4) Adequate Representation
Rule 23(a)(4) also requires that “the representative parties will fairly and adequately protect the interests of the class.” In the Second Circuit, adequacy of representation involves inquiry as to whether: 1) the plaintiffs intеrests are antagonistic to the interest of other members of the class and 2) the plaintiffs attorneys are qualified, experienced and able to conduct the litigation. Baffa v. Donaldson, Lufkin & Jenrette Sec. Corp.,
Both of the criteria recognized by the Second Circuit are satisfied in this case. The named plaintiffs’ interests are directly aligned with those of the absent class members: they are purchasers of Celera common stock who suffered significant losses as a result of the investments. Their attorneys are all qualified, experienced and able to conduct complex securities litigation. Although the defendants claim that Bеrlin and Voung are inadequate because they do not fully understand the factual allegations or procedural issues in this case, the Court finds that these concerns are not supported by the record, and that both Berlin and Voung will be adequate representatives of the class. Moreover, this conclusion is buttressed by the adequacy and competence of the counsel
In sum, the Court finds that all of the criteria of Rule 23(a) have been established.
5) Rule 28(b)
Having established that the plaintiffs meet the requirements of Rule 23(a), the Court must next determine whether they also meet the requirements of Rule 23(b). See Amchem Products, Inc. v. Windsor,
the court finds that the questions of law or fact common to the members of the class predominate over any questions affecting only individual members, and that a class action is superior to other available methods for the fair and efficient adjudication of the controversy. The matters pertinent to the findings include: (A) the interest of members of the class in individually controlling the prosecution or defense of separate actions; (B) the extent and nature of any litigation concerning the controversy already commenced by or against members of the class; (C) the desirability or undesirability of concentrating the litigation of the claims in the particular forum; (D) the difficulties likely to be encountered in the management of a class action.
Fed.R.Civ.P. 23(b)(3). As the Supreme Court has summarized: “To qualify for certification under Rule 23(b)(3), a class must meet two requirements beyond the Rule 23(a) prerequisites: Common questions must ‘predominate over any questions affecting only individual members’ [“the predominance requirement”]; and class resolution must be ‘superior to other available methods for the fair and efficient adjudication of the controversy.’ [“the superiority requirement”]” Am-chem Products,
The predominance requirement “tests whether proposed classes are sufficiently cohesive to warrant adjudication by representation.’ ” Moore v. PaineWebber, Inc.,
The defendants maintain that the proposed class does not meet the predominance test of Rule 23(b) because common questions will not predominate at trial of this action. Essentially, the defendants maintain a truth in the market defense-that the information which the plaintiffs’ claim was missing from the prospectus was made publicly known pri- or to that date-predominates, and therefore individualized issues concerning each particular class member’s knowledge of that information will become a distracting central issue at trial of this matter.
The superiority requirement “asks the court to balance, in terms of fairness and efficiency, the merits of a class action against those of alternative available methods of adjudication.” In re Warfarin Sodium Antitrust Litigation,
(A) the interest of members of the class in individually controlling the prosecution or defense of separate actions; (B) the extent and nature of any litigation concerning the controversy already commenced by or against members of the class; (C) the desirability or undesirability of concentrating the litigation of the claims in the particular forum; (D) the difficulties likely to be encountered in the management of a class action.
Given the complexities of a securities litigation case, the interest of individual stockholders in controlling the prosecution of separate actions is low. The parties have not identified any other cases involving Celera common stock, which further may indicate a lack of interest in individual prosecution of claims. In re Warfarin Sodium Antitrust Litigation,
Consequently, the Court finds that the plaintiffs have satisfied both of the requirements of Rule 23(b).
V. Conclusion
The Court grants the plaintiffs’ request to certify this action under Rule 23(a) and (b)(3) [Doc. # 57] with Berlin and Voung as lead plaintiffs аnd class representatives. Pursuant to the request made in the complaint and the instant motion for certification, the class consists “of all persons who purchased PE Corporation Celera Genomics Group (‘Celera’) common stock in a Secondary Public Offering conducted by PE Corporation on or about February 29, 2000 and who were damaged thereby.”
Notes
. The facts are taken from the complaint. See Shelter Realty Corp. v. Allied Maint. Corp.,
. Genomics is the study of all the genetic information of a species.
. Under the truth on the market defense, "a misrepresentation is immaterial if the information is already known to the market because the misrepresentation cannot then defraud the market.” Ganino v. Citizens Utilities Co.,
